MX350718B - Vacuna de rinitis equina. - Google Patents

Vacuna de rinitis equina.

Info

Publication number
MX350718B
MX350718B MX2013010125A MX2013010125A MX350718B MX 350718 B MX350718 B MX 350718B MX 2013010125 A MX2013010125 A MX 2013010125A MX 2013010125 A MX2013010125 A MX 2013010125A MX 350718 B MX350718 B MX 350718B
Authority
MX
Mexico
Prior art keywords
equine rhinitis
equine
rhinitis vaccine
vaccine
immunogenic compositions
Prior art date
Application number
MX2013010125A
Other languages
English (en)
Other versions
MX2013010125A (es
Inventor
Wayne Hayes Phillip
J Hennessy Kristina
Viel Laurent
Diaz Mendez Andres
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of MX2013010125A publication Critical patent/MX2013010125A/es
Publication of MX350718B publication Critical patent/MX350718B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a composiciones inmunógenas contra virus de rinitis equina, en particular virus de rinitis equina A y B y métodos para su uso y su preparación. Las composiciones inmunógenas, en modalidades alternativas, también incluyen otros agentes patógenos de equinos.
MX2013010125A 2011-03-14 2012-03-12 Vacuna de rinitis equina. MX350718B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452390P 2011-03-14 2011-03-14
US201161510226P 2011-07-21 2011-07-21
PCT/US2012/028706 WO2012125525A2 (en) 2011-03-14 2012-03-12 Equine rhinitis vaccine

Publications (2)

Publication Number Publication Date
MX2013010125A MX2013010125A (es) 2013-10-07
MX350718B true MX350718B (es) 2017-09-14

Family

ID=45876924

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013010125A MX350718B (es) 2011-03-14 2012-03-12 Vacuna de rinitis equina.
MX2017004273A MX385188B (es) 2011-03-14 2012-03-12 Vacuna de rinitis equina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017004273A MX385188B (es) 2011-03-14 2012-03-12 Vacuna de rinitis equina.

Country Status (12)

Country Link
US (1) US9187730B2 (es)
EP (2) EP2686012B1 (es)
AR (1) AR085800A1 (es)
AU (2) AU2012229192B2 (es)
BR (2) BR122019023542B1 (es)
CA (2) CA2829226C (es)
ES (2) ES2842595T3 (es)
MA (1) MA35303B1 (es)
MX (2) MX350718B (es)
NZ (1) NZ614147A (es)
TW (1) TW201300537A (es)
WO (1) WO2012125525A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019023542B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Vetmedica, Inc Composição imunogênica compreendendo uma ou mais cepas de vírus da rinite equina b (erbv) inativado e seu método de preparação
WO2016083287A1 (en) * 2014-11-24 2016-06-02 Intervet International B.V. Inactivated equine influenza virus vaccines
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever
US12239702B2 (en) 2017-12-04 2025-03-04 Intervet Inc. Vaccination with replicon particles and oil adjuvant

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
CA2410579C (en) 2000-05-26 2010-04-20 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses
US8496939B2 (en) 2001-02-28 2013-07-30 Intervet International B.V. Injectable water-in-oil emulsions
CA2440593A1 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AUPR472501A0 (en) 2001-05-02 2001-05-24 Council Of The Queensland Institute Of Medical Research, The Equine rhinitis a virus antigens
RS53184B (sr) 2001-07-27 2014-06-30 Zoetis W Llc Kompozicija vakcine za primenu u sprečavanju ili ublažavanju encefalitisa zapadnog nila kod ekvida
JP5164305B2 (ja) 2001-10-19 2013-03-21 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 動物におけるフラビウイルス感染を予防および治療する方法
MXPA05005140A (es) 2002-11-15 2005-08-19 Acambis Inc Vacuna contra el virus del nilo occidental.
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
EP1664786B1 (en) 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EP1645283A1 (en) 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
NZ564375A (en) 2005-06-24 2010-02-26 Intervet Int Bv Inactivated chimeric flavivirus vaccines and related methods of use
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
WO2007042884A1 (en) 2005-10-07 2007-04-19 Pfizer Products Inc. Vaccines and methods to treat canine influenza
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
EP1945251B1 (en) 2005-11-01 2012-02-08 Intervet International BV Prime boost vaccine for the protection of equines against equine influenza
US7455842B2 (en) 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
KR100850545B1 (ko) 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
CN102348466B (zh) 2008-08-29 2014-05-07 贝林格尔.英格海姆维特梅迪卡有限公司 西尼罗病毒疫苗
BR122019023542B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Vetmedica, Inc Composição imunogênica compreendendo uma ou mais cepas de vírus da rinite equina b (erbv) inativado e seu método de preparação

Also Published As

Publication number Publication date
BR122019023542B1 (pt) 2022-02-15
BR112013023354A2 (pt) 2016-12-06
AU2017201526A1 (en) 2017-03-30
AU2017201526B2 (en) 2019-07-18
AR085800A1 (es) 2013-10-30
WO2012125525A3 (en) 2013-02-28
CA3018230A1 (en) 2012-09-20
NZ708320A (en) 2016-08-26
ES2842595T3 (es) 2021-07-14
EP2772266B1 (en) 2019-07-31
EP2686012B1 (en) 2020-12-02
CA2829226A1 (en) 2012-09-20
EP2686012A2 (en) 2014-01-22
MX385188B (es) 2025-03-14
MX2013010125A (es) 2013-10-07
TW201300537A (zh) 2013-01-01
EP2772266A1 (en) 2014-09-03
MA35303B1 (fr) 2014-08-01
BR112013023354B1 (pt) 2022-02-15
CA2829226C (en) 2023-01-03
AU2012229192A1 (en) 2013-08-29
WO2012125525A2 (en) 2012-09-20
US9187730B2 (en) 2015-11-17
NZ614147A (en) 2015-08-28
AU2012229192B2 (en) 2017-04-20
US20120237543A1 (en) 2012-09-20
ES2748555T3 (es) 2020-03-17
AU2017201526C1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
MX383065B (es) Mutantes de virus de influenza y usos para los mismos.
MX2016003216A (es) Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
CU20150052A7 (es) Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina
CY1116835T1 (el) Νεο ευρωπαϊκο στελεχος toy prrsv
CU20130157A7 (es) 4 - aril- n- fenil- 1,3,5- triazin- 2- aminas que contienen un grupo sulfoximina
CL2013002712A1 (es) Composicion inmunogénica para modular sistema inmune que comprende agentes con patrones asociados a bacterias, virus, hongos y levaduras, protozoos, helmintos y/o priones; uso para tratar enfermedades autoinmunes o infecciosas.
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
EP2806891A4 (en) Parainfluenza virus 5 based vaccines
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
MX2021010060A (es) Produccion de virus en huevos aviares.
BR112014001049A2 (pt) método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
MX350718B (es) Vacuna de rinitis equina.
BR112013019924A8 (pt) Composições para cuidado oral
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants
MY171497A (en) Crystalline forms of dihydropyrimidine derivatives
WO2014008475A3 (en) Compositions and methods related to viral vaccines

Legal Events

Date Code Title Description
FG Grant or registration